RemeGen Swings to Profit in 2026 on Strong Core Product Sales
During the reporting period, the company's core products, Telitacicept and Disitamab vedotin, continued to post growing domestic sales revenue. RemeGen (688331) announced on August 5, 2026 that it had swung from a loss to a profit in the reporting period compared with the same period in 2025.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 70/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.